Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up to $2.89

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) shares gapped up prior to trading on Friday . The stock had previously closed at $2.89, but opened at $2.96. Lexicon Pharmaceuticals shares last traded at $2.91, with a volume of 199,971 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LXRX. Jefferies Financial Group began coverage on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 7th. They issued a “hold” rating and a $3.00 target price for the company. StockNews.com began coverage on shares of Lexicon Pharmaceuticals in a research report on Thursday. They issued a “sell” rating for the company.

Lexicon Pharmaceuticals Price Performance

The company’s fifty day moving average price is $2.55 and its 200 day moving average price is $2.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 5.38 and a current ratio of 5.38. The firm has a market capitalization of $570.58 million, a price-to-earnings ratio of -4.85 and a beta of 1.33.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) last posted its quarterly earnings results on Thursday, March 2nd. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Lexicon Pharmaceuticals had a negative net margin of 87,620.63% and a negative return on equity of 105.14%. The business had revenue of $0.03 million during the quarter. Equities research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of LXRX. The Manufacturers Life Insurance Company boosted its stake in Lexicon Pharmaceuticals by 126.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 35,943 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 20,065 shares during the period. Great West Life Assurance Co. Can boosted its stake in Lexicon Pharmaceuticals by 705.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 37,343 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 32,708 shares during the period. BVF Inc. IL boosted its stake in Lexicon Pharmaceuticals by 14.1% during the 3rd quarter. BVF Inc. IL now owns 16,149,179 shares of the biopharmaceutical company’s stock valued at $38,758,000 after purchasing an additional 2,000,000 shares during the period. Virtu Financial LLC acquired a new position in Lexicon Pharmaceuticals during the 3rd quarter valued at about $32,000. Finally, Point72 Asset Management L.P. acquired a new position in Lexicon Pharmaceuticals during the 3rd quarter valued at about $8,672,000.

About Lexicon Pharmaceuticals

(Get Rating)

Lexicon Pharmaceuticals, Inc engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes.